-
Mupirocin Global Buyers List
Mupirocin is an antibiotic that is used to treat bacterial skin infections, such as impetigo, folliculitis, and cellulitis. It is also used to prevent infections in people with weakened immune systems. Mupirocin is available as a cream, ointment, and nasal spray. Mupirocin Global Buyers List Mupirocin is a generic drug that is available in many countries around the world. The following is a list of some of the major global buyers of mupirocin: TEVA PHARMACEUTICAL USA INC GLENMARK PHARMACEUTICALS LTD CHROMACHEMIE LABORATORY PRIVATE LIMITED LABORATORIOS AC FARMA S A GLAXOSMITHKLINE PHARMACEUTICALS LIMITED TEVA PHARMACEUTICALS USA INC GLAXOSMITHKLINE MEXICO SA DE CV GLENMARK PHARMACEUTICALS LIMITED GLENMARK PHARMACEUTICALS INC USA INSTITUTO QUIMIOTERAPICO…
-
Glimepiride Global Buyers List
Glimepiride is a popular oral antidiabetic medication used to treat type 2 diabetes. It works by stimulating the beta cells in the pancreas to produce more insulin and by making the body’s tissues more sensitive to insulin. Glimepiride is available as a generic medication and under various brand names, including Amaryl, Daonil, and Glibenese. It is also available in combination with other medications, such as metformin and pioglitazone. Global Buyers List The following is a list of some of the leading global buyers of glimepiride: CÔNG TY TNHH DƯỢC PHẨM VÀ TRANG THIẾT BỊ Y TẾ HOÀNG ĐỨC KAUSTUBHA SCIENTIFIC RESEARCH LABORATORYPRIVATE LI ООО GRAND PHARM TRADE ULTRA INTERNATIONAL OOO…
-
The Involution of Weight Loss Drugs: Lessons from the Failure of Novartis’ MBL949
On the evening of July 18, Novartis announced its second quarter report for 2023, and its performance exceeded expectations, but a decision in the report was caught by many investors—due to the poor efficacy of the second phase trial, the company gave up the research and development of MBL949. MBL949 is a GDF15 receptor agonist and one of Novartis’ important weight loss drug pipeline assets. According to data, GDF15 can reduce people’s desire for high-fat diets and achieve weight loss by promoting muscle energy consumption; Johnson & Johnson has achieved some success in this target, while Eli Lilly has voluntarily terminated the development of GDF15 agonists. The failure of Novartis…
